We are live on ! Find out more
TARS icon

Tarsus Pharmaceuticals
TARS

116 hedge funds and large institutions have $692M invested in Tarsus Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 48 increasing their positions, 22 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

552% more call options, than puts

Call options by funds: $2.99M | Put options by funds: $458K

118% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 22

65% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 17

31% more capital invested

Capital invested by funds: $529M → $692M (+$162M)

11.77% more ownership

Funds ownership: 91.33% → 103.11% (+12%)

10% more funds holding

Funds holding: 105 → 116 (+11)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

Holders
116
Holders Change
+11
Holders Change %
+10.48%
% of All Funds
1.69%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
28
Increased
48
Reduced
22
Closed
17
Calls
$2.99M
Puts
$458K
Net Calls
+$2.53M
Net Calls Change
+$2.26M

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$64.1M
2
PBA
Paradigm Biocapital Advisors
New York
+$17.1M
3
BlackRock
BlackRock
New York
+$5.11M
4
RI
RTW Investments
New York
+$4.54M
5
NCM
Nantahala Capital Management
Connecticut
+$4M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$13.4M
2
Millennium Management
Millennium Management
New York
-$10.2M
3
VC
Vivo Capital
California
-$7.98M
4
CAM
Cormorant Asset Management
Massachusetts
-$6.68M
5
SCM
Soleus Capital Management
Connecticut
-$4.44M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
101
Fidelity Investments
Massachusetts
$32.7K +$8.57K +513 +46%
HNB
102
Huntington National Bank
Ohio
$30.4K – – –
VWM
103
Venturi Wealth Management
Texas
$17.4K – – –
SIC
104
Salem Investment Counselors
North Carolina
$6.08K – – –
Osaic Holdings
105
Osaic Holdings
Arizona
$3.65K – – –
US Bancorp
106
US Bancorp
Minnesota
$2.33K +$1.92K +115 New
Daiwa Securities Group
107
Daiwa Securities Group
Japan
$2K – – –
LC
108
Lindbrook Capital
California
$1.9K – – –
Russell Investments Group
109
Russell Investments Group
United Kingdom
$1.56K +$868 +52 +208%
SWM
110
Spire Wealth Management
Virginia
$1.55K -$1.34K -80 -55%
SPIA
111
Steward Partners Investment Advisory
New York
$1.2K – – –
Comerica Bank
112
Comerica Bank
Texas
$1.15K +$952 +57 New
GI
113
GAMMA Investing
California
$572 +$351 +21 New
FFA
114
Farther Finance Advisors
California
$243 +$200 +12 New
Nisa Investment Advisors
115
Nisa Investment Advisors
Missouri
$203 -$250 -15 -60%
PNC Financial Services Group
116
PNC Financial Services Group
Pennsylvania
$101 +$83 +5 New
DM
117
Deerfield Management
New York
– -$13.4M -754,042 Closed
SCM
118
Soleus Capital Management
Connecticut
– -$4.44M -250,000 Closed
Renaissance Technologies
119
Renaissance Technologies
New York
– -$1.9M -106,900 Closed
UOC
120
UBS O'Connor
Illinois
– -$982K -55,262 Closed
CWM
121
CIBC World Markets
New York
– -$889K -50,000 Closed
GCM
122
Ghisallo Capital Management
Massachusetts
– -$889K -50,000 Closed
Tudor Investment Corp
123
Tudor Investment Corp
Connecticut
– -$889K -50,000 Closed
ECM
124
Endurant Capital Management
California
– -$847K -47,649 Closed
OQS
125
Occudo Quantitative Strategies
Florida
– -$777K -43,707 Closed
2 3 4
5
6

TARS Hedge Fund Activity: Q4 2023 in Review

116 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q4 2023, worth a combined $692M — up 31% from $529M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new TARS positions and 17 closed out — a net gain of 11 holders — while 48 added to existing stakes and 22 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $64.1M. The largest seller was Deerfield Management, exiting entirely with an estimated $13.4M sold.

  • 116 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q4 2023, up from 105 in Q3 2023.
  • Funds reported $692M of Tarsus Pharmaceuticals stock for Q4 2023, up 31% quarter-over-quarter.
  • 28 funds opened new Tarsus Pharmaceuticals positions in Q4 2023 and 17 closed out, a net change of +11 holders.
  • The largest Tarsus Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $64.1M added.
  • The largest Tarsus Pharmaceuticals seller in Q4 2023 was Deerfield Management, an estimated $13.4M sold.

Based on aggregated 13F filings for Q4 2023.